Purpose: We tested the diagnostic accuracy of shear wave elastography to detect and phenotypically characterize prostate cancer compared with whole mount radical prostatectomy histopathology. Materials and Methods: In this prospective, protocol driven, diagnostic accuracy study 212 consecutive men undergoing laparoscopic radical prostatectomy for clinically localized prostate cancer were recruited. Quantitative stiffness data on the prostate gland were obtained in each patient using an endocavitary transrectal transducer before laparoscopic radical prostatectomy. Those data were compared with a detailed histopathological examination of the radical prostatectomy specimen using 3-dimensional printing mold based technology to ensure an improved image histology orientation. ROC curves were assessed between the groups. Results: Quantitative stiffness data estimated in kPa were significantly higher in malignant compared with benign areas. At a cutoff of 82.6 kPa the sensitivity and specificity of shear wave elastography were 96.8% and 67.8%, respectively (p <0.01). Significant differences were observed for different cancer grades with the Young moduli, including 91.6, 102.3 and 131.8 kPa for low grade (Gleason score 6), intermediate grade (Gleason score 7) and high grade (Gleason score 8 or greater) prostate cancer, respectively (p <0.05). Shear wave elastography also detected capsular breaches with significant prediction of prostate cancer pathological staging. Potential limitations include selection bias and study being single center site. Conclusions: Quantitative shear wave elastography via the transrectal approach accurately detected cancer foci and revealed significant differences between cancerous and benign tissue. Moreover, this technique can be used to reliably phenotype prostate cancer aggressiveness.
patients, particularly those with insignificant PCa. 3, 4 Patients diagnosed with localized PCa are offered active surveillance or radical treatments. Radical treatments are invariably accompanied by high adjunct health risks and they are financially costly. Particularly patients pay a high price for low risk disease. Accurate detection of clinically significant PCa by noninvasive imaging may allow for improved risk stratification and optimal selection of men for active surveillance, focal therapy and/or radical therapy.
TRUS is a noninvasive imaging method. Compared with other imaging techniques such as MRI and computerized tomography TRUS is more practical in the clinical setting with the advantage of being a realtime method that is cost-effective and free of radiation. 5 Nevertheless, traditional B-mode and Doppler ultrasound images have limited sensitivity and/or specificity and they have not proved to unequivocally improve the diagnostic accuracy of PCa detection. 6 Malignant tissue associated with the prostate gland is stiffer compared to the surrounding benign enlargement. This is well recognized by clinicians who perform DRE. Information derived from DRE is important for the clinical decision making process. However, independently performed DRE has poor sensitivity and specificity to assess small and anterior lesions. 7 Accordingly with the recent introduction of TRUS SWE it is possible to assess the tissue stiffness of even nonpalpable small lesions. The SWE technique is based on measurements of shear wave speed through target tissues, which can be used to dynamically map and reflect tissue stiffness (the Young modulus) properties in real time. 8, 9 Preliminary studies using SWE have been promising. They suggest that by implementing this technique 10 there is the potential for improved cancer detection and phenotyping. 11 As briefly described, a shear wave pulse is generated in target tissue by multiple focused ultrasound beams. The difference in the speed of the shear waves is due to the stiffness properties of the propagating medium. This difference is captured by piezoelectrodes in the transducer, including all of these scattered shear waves, and plotted in a pseudocolor coded map with shear wave speed in m per second or the Young modulus in kPa in pixels overlapped with B-mode ultrasound ( fig. 1 ).
We and others previously reported SWE to detect and phenotype PCa, and noted the strong diagnostic performance of this methodology.
11e15 Nevertheless, to our knowledge there have been no largescale prospective studies to date testing the diagnostic accuracy of SWE compared with radical prostatectomy histology as the reference standard. Figure 2 . Histopathology results compared with 12-region SWE images obtained in 73-year-old patient. a, whole set of prostate slices atAccordingly in this prospective study we aimed to determine 1) the diagnostic accuracy of transrectal SWE compared with radical prostatectomy final pathology findings and 2) the reliability of transrectal SWE with respect to accurately characterizing and phenotyping various PCa grades, including establishing and validating cutoffs for benign and significant PCa.
METHODS

Study Population
This was a prospective, protocol driven study with prior ethical and institutional approval (REC [ The primary outcome of the study was to determine the diagnostic accuracy of transrectal SWE to detect and phenotype PCa. The secondary outcome was to determine the ability of the technology to detect clinically significant PCa and define SWE risk threshold cutoff values. The presence of clinically significant PCa was based on a combination of Gleason grade greater than 6 and a physical cancer burden greater than 5 mm. 17 Study inclusion criteria were men with confirmed PCa on TRUS guided biopsies coupled with imaging suggestive of clinically localized disease (cT2 or less). Based on the calculated sample size 170 patients were required to address the primary outcome. All significance calculations were 2-sided and based on a ¼ 0.05, 0.95 power and an effect size of 0.3. We recruited 212 men in the study to account for an estimated 20% loss of data due to participant dropout, poor images, technical difficulties, etc.
Transrectal Ultrasound Shear Wave Elastography Protocol Index Test
TRUS SWE was performed by an experienced urologist with more than 10 years of experience on the day of LRP in all participants using an endocavity AixplorerÒ ultrasound transducer through the rectal wall, focusing on the prostate and avoiding any pressure on the transducer. During patient imaging the prostate gland was scanned in the axial and sagittal planes from base to apex every 4 to 6 mm. Images were quantitatively analyzed following examinations and imaging data of successive planes were used to construct offline 3-dimensional images of the prostate. Participant images were then used to produce customized prostate molds, which served to guide prostate slicing postoperatively.
Radical Prostatectomy Histopathology as Reference Test
The prostate specimens of all eligible participant were sectioned according to our recently published method. 18 Briefly, we applied rapid prototyping methodology using prostate images. Prostate specimens were placed in molds for sectioning to ensure the orientation between histology and imaging slices ( fig. 2, a) . 18, 19 All prostate sections were analyzed by an experienced uropathologist with more than 20 years of experience while blinded to SWE image findings. Margin status, including pathological disease stage, was defined and compared to SWE imaging.
Statistical Analyses
All statistical analyses were done with SPSSÒ, version 22 . Stiffness values of cancerous tissue and surrounding benign tissues were compared using the paired Student t-test. The a level was set at 0.05 to determine 2-tailed significance. ROC curves were plotted for stiffness values followed by application of the maximum Youden index (sensitivity e [1 e specificity]), indicating that sensitivity and specificity are equally important to determine optimal cutoff values between tissues that were cancerous or benign. 20 For cross validation and control purposes tenfold cross validation was implemented. We randomly split the data into 10 subgroups of identical size. Each subgroup was selected and served as a testing database while the remaining 9 subgroups were used for training. The performance was repeated for an additional 9 times with different subgroups serving as the testing database.
Correlations between cancer stiffness and GSs were calculated. Elasticity values representing each GS were graphed using box and whisker plots. Finally, tissue stiffness was correlated with histopathology outcomes to define significant PCa.
RESULTS
Mean AE SD cohort age was 67.6 AE 5.4 years, mean PSA was 11.8 AE 8.1 ng/ml (range 0.9 to 47) and mean prostate volume was 66.9 AE 30.4 ml (range 20 to 207). Only 7 participants (3%) had GS 6 disease (3 þ 3) and more than half had GS 7, including 3 þ 4 in 48% and 4 þ 3 in 17%. Notably almost a third of participants demonstrated high GS disease, including 3 þ 5 in 10%, 4 þ 4 in 1% and 4 þ 5 in 21% (table 1) .
Two levels of analysis were performed. On participant level analyses only averaged index lesion scores were considered when assessing SWE performance for low grade PCa (GS 6) fig. 4 ). Tumor level analyses were done in 511 cancer foci from a total of 2,544 regions, including 12 regions from a total of 212 patients which were marked from whole mount pathology ( fig. 2, b) . Table 4 shows the cancer distribution. Of the 511 cancer foci 57 (11.2%), 126 (24.7%) and 328 (64.1%) were less than 5, 5 to 10 and greater than 10 mm, respectively. GS 3 þ 4 was the most common cancer, accounting for 296 of all 511 cancer foci (57.9%). Table 4 shows that SWE identified cancer on the distribution map using 82.6 kPa as a cutoff value. Table 5 shows the stiffness of the identified cancers. After considering the size of all cancers there was no significant difference in tissue stiffness across the different sizes of cancer foci. However, the mean value of the Young modulus of GS 6 to 9 increased from 91.9 (GS 3 þ 3) to 126.7 kPa (GS 4 þ 5). The mean value of all lesions was 106.3 kPa. Table 4 also shows that the sensitivity of SWE to detect less than 5 mm cancers was much lower than that of 5 to 10 and greater than 10 mm cancers (30.9% vs 68.5% and 92.4%, respectively). Only 9 of 32 cancers that were GS 6 and less than 5 mm were found by SWE. Figure 5 shows the diagnostic results of clinically significant cancer as well as the SWE outcomes of sensitivity, specificity, and positive and negative values compared with histopathology results. The sensitivity, specificity, and positive and negative values of SWE for clinically significant cancer were 88.6% (95% CI 85.1e91.6), 97.3% (CI 96.6e98.0), 86.3% (CI 83.0e89.1) and 97.8% (CI 97.2e98.3), respectively (p <0.05). Figure 6 shows the representative ultrasound and pathology images of a 70-year-old patient. MRI was negative, biopsy showed GS 3 þ 3 and SWE was as high as 300 kPa and suggested prostate capsular breach in the peripheral area ( fig. 6 ). Prostate stones were seen on B-mode ultrasound and LRP pathology images confirmed GS 4 þ 5 cancer with extraprostatic extension.
In the entire cohort when pathological stage was more aggressive, we were able to detect margin status/capsular breaches with 73.9% sensitivity (68 of 92 cases) and 80.8% specificity (97 of 120) (p <0.05, table 6). All patients with capsular breach had high grade disease (greater than GS 7) or large lesions (greater than 10 mm). When cancer size was more than 10 mm and within 2 mm of the prostate edge, there was a 90% risk of a positive surgical margin on prostate whole mount histopathology.
DISCUSSION
The observations of the current study illustrate that TRUS SWE demonstrated strong diagnostic performance in patients with clinically localized PCa.
We found that transrectal SWE could identify PCa coupled with an ability to distinguish between clinically significant and low risk PCa. We also found that tissue stiffness measurements (the Young modulus) estimated at 12 prostate gland regions using a cutoff of 82.6 kPa identified significant differences between benign and malignant tissue. The cutoff value was based on internal validation using the tenfold cross validation method. We particularly noted that significant lesions (GS 7 or greater) showed higher Young moduli compared with benign and nonsignificant lesions (GS 6 or less). Lastly TRUS SWE also demonstrated strong performance to predict cancer stage and surgical margin status. To our knowledge these data represent a significant contribution to the body of knowledge associated with transrectal B-mode ultrasonography screening for PCa.
Despite various innovative imaging technologies aimed at improving PCa detection and characterization, calculations of the individual risk of clinically significant PCa remain poor. Histology using prostate biopsies remains the gold standard of PCa diagnosis. However, TRUS guided biopsy is an invasive procedure with known risks, including acute bleeding, sepsis, urinary retention and even death.
21e23 Therefore, image fusion techniques, and Doppler and contrast enhanced ultrasound methods Figure 6 . Example of 70-year-old patient with MRI negative, biopsy GS 3 þ 3 findings. a, SWE shows high 300 kPa tissue stiffness and prostate capsular breach in peripheral area. b, prostate stones shown on B-mode ultrasound as hypo-intensive signal and confirmed in prostate specimen slice. c, whole mount prostate pathology confirmed high grade (GS 4 þ 5) cancer with pT3 extraprostatic extension. Neg:*  97  23  120  pT2a  9  0  9  pT2b  1  2  3  pT2c  64  12  76  pT3a  22  6  28  pT3b  1  3  4  Pos:  24  68  92  pT2a  2  0  2  pT2b  0  0  0  pT2c  5  25  30  pT3a  10  29  39  pT3b  7  12  19  pT4  0  2  2  Totals  121  91  212 * No pT4 cancer.
have been used to improve the detection of PCa while also aiming to reduce the number of biopsies and minimizing adverse events.
24e27
A number of reports, including recent guidelines, have mentioned the improved diagnostic performance of SWE with respect to PCa. 11, 15 However, previous studies lacked power and mostly used grayscale based ultrasound guided biopsies as the reference standard. Accordingly there are many original features of the current series. 1) To our knowledge our study represents the largest cohort in which to analyze the usefulness of SWE compared to final histopathology reports of specimens using whole mount radical prostatectomy specimens. 2) We confirmed that the orientation of what was observed on imaging was consistent with final histopathology slides by implementing rapid prototyping and mold based technology. 18 In our study we also observed that SWE showed strong diagnostic performance regarding different prostatic tissues of various regions. Cancer foci could be detected or visually color coded by real-time SWE. With this technique we noted that benign tissue had appreciably lower stiffness than cancer foci. Using this advanced SWE ultrasound imaging technique we also identified an accurate cutoff value to distinguish suspicious cancer areas from benign prostatic tissue. Tenfold cross validation was performed and the average cutoff value was 82.6 kPa (table 3) . Accordingly these observations have immediate implications for patient therapy and followup care. For example, 1) low grade PCa might not require active treatment and 2) if PCa can be reliably identified, followup care can be closely tracked to help decrease the mistreatment rate with high diagnostic performance. Further, the ability of SWE to differentiate among different cancer grades could be tested for reliable monitoring in an active surveillance cohort.
The higher cutoff compared to that in previous studies was due to a higher proportion of men with high grade disease. The current series also represented unscreened men for prostate cancer. It may be skewed because most men with significant disease elect radical surgery as the treatment option. Our cutoff was based on a robust cross validation technique and a better reference standard of radical prostatectomy histology.
Positive surgical margins and extraprostatic extension of cancer may cause increased biochemical recurrence. 28 These types of cases require extended PSA followup and may also necessitate salvage treatments after failed LRP. Therefore, preoperative testing with SWE has shown the ability to predict positive surgical margins while also demonstrating the potential to assist in surgical planning and predicting future adjuvant treatment.
There are several limitations to the current study. Since we estimated the diagnostic performance of SWE in men with histopathologically confirmed PCa, there was selection bias. Whether similar results would also be observed in men with suspected PCa or in another screening setting needs further study. A potential learning curve associated with applying the SWE technique was not assessed and procedures were performed by a single surgeon at a single center site. Nevertheless, the robust protocol of the current study coupled with the encouraging findings provide support that further research is needed in this area.
CONCLUSIONS
TRUS SWE imaging demonstrated high reliability and accurately distinguished PCa from benign tissues while identifying a cutoff value of stiffness. Moreover, SWE technology provided high reliability in distinguishing PCa based on phenotype (PCa grade). Finally, the technology also had good diagnostic performance to detect margin status and disease stage.
PCa detection remains a problem. Random TRUS biopsies have been the standard of care but they can often miss cancers and under grade the cancers that are identified. MRI has had success in identifying clinically significant PC and it may be helpful in active surveillance.
1 SWE is a new technique that evaluates tissue stiffness. 2 As most PCa is stiffer than normal prostate it can be detected by SWE and the stiffness appears to correlate with Gleason scores. However, benign prostatic nodules are also stiff, making evaluation of the central gland problematic with SWE. MRI does not suffer from this problem.
In our experience SWE has better accuracy in the peripheral zone and MRI has better accuracy in the central gland. An optimal method of diagnosing PCa may be to perform magnetic resonance elastography and then perform MRI-ultrasound fusion for the biopsy. At that time the MRI lesions and the SWE lesions can be biopsied. Targeting the stiffest area in a lesion will most likely provide the best correlation with Gleason score.
In this study Wei et al determined a cutoff value substantially higher than that of other authors. This is most likely due to compression of the prostate during the examination. Whenever tissues are compressed, stiffness increases, whether benign or malignant. 3 The explanation of the authors of the difference is most likely not valid. Evaluating normal prostate stiffness can be used to confirm that compression is not applied. In this study the normal stiffness values are also substantially increased.
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